INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///

NEWS

Filter By
  • image description

    Ayala Pharmaceuticals

    As part of a larger collaboration, Ayala Pharmaceuticals has chosen Tempus as the preferred sequencing partner to support in screening and recruiting patients for its TENACITY AL101 study, a therapy targeting triple negative breast cancer. The collaboration aims to identify patients with various NOTCH alterations to accurately match and enroll them into the TENACITY trial operating in the U.S., Euro...